Type of information: Series D financing round
Company: Adrenomed (Germany)
Investors: HBM Healthcare Investments (Switzerland) Wellington Partners (Germany - UK)
Amount: € 24 million
Funding type: series D financing round
- The new funds will be invested in the clinical development program of lead product candidate adrecizumab. Adrecizumab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma adrenomedullin concentrations (bio-ADM®). This first-in-class monoclonal antibody is targeting adrenomedullin, an essential regulator of vascular integrity, for treatment of life-threatening conditions associated with systemic inflammatory response (SIRS) and increased vascular leakage, congestion and shock. The most important target indications are sepsis and septic shock.
- • On November 26t, 2018, Adrenomed, the vascular integrity company, announced the closing of a € 24 million series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors.
Therapeutic area: Inflammatory diseases